An Open-Label, Multicenter Phase I Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics And Maximum Tolerated Dose Of VIP152 (BAY 1251152) In Subjects With Advanced Cancer